BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22532859)

  • 21. Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years.
    Kapoor A; Bartha R; Black SE; Borrie M; Freedman M; Gao F; Herrmann N; Mandzia J; Ozzoude M; Ramirez J; Scott CJM; Symons S; Fischer CE; Frank A; Seitz D; Wolf MU; Verhoeff NPLG; Naglie G; Reichman W; Masellis M; Mitchell SB; Tang-Wai DF; Tartaglia MC; Kumar S; Pollock BG; Rajji TK; Finger E; Pasternak SH; ; Swartz RH
    J Alzheimers Dis; 2020; 74(3):747-757. PubMed ID: 32116253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir.
    Hornberger J; Bae J; Watson I; Johnston J; Happich M
    Curr Med Res Opin; 2017 Apr; 33(4):675-685. PubMed ID: 28035842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease.
    Chincarini A; Bosco P; Calvini P; Gemme G; Esposito M; Olivieri C; Rei L; Squarcia S; Rodriguez G; Bellotti R; Cerello P; De Mitri I; Retico A; Nobili F;
    Neuroimage; 2011 Sep; 58(2):469-80. PubMed ID: 21718788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic differentiation of mild cognitive impairment due to Alzheimer's disease using a hippocampus-dependent test of spatial memory.
    Moodley K; Minati L; Contarino V; Prioni S; Wood R; Cooper R; D'Incerti L; Tagliavini F; Chan D
    Hippocampus; 2015 Aug; 25(8):939-51. PubMed ID: 25605659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How early can we predict Alzheimer's disease using computational anatomy?
    Adaszewski S; Dukart J; Kherif F; Frackowiak R; Draganski B;
    Neurobiol Aging; 2013 Dec; 34(12):2815-26. PubMed ID: 23890839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
    Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
    Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions.
    Wimo A; Handels R; Winblad B; Black CM; Johansson G; Salomonsson S; Eriksdotter M; Khandker RK
    J Alzheimers Dis; 2020; 75(3):891-902. PubMed ID: 32390617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.
    Robinson RL; Rentz DM; Andrews JS; Zagar A; Kim Y; Bruemmer V; Schwartz RL; Ye W; Fillit HM
    J Alzheimers Dis; 2020; 75(2):437-450. PubMed ID: 32250304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
    King-Robson J; Wilson H; Politis M;
    J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting the conversion of mild cognitive impairment to Alzheimer's disease based on the volumetric measurements of the selected brain structures in magnetic resonance imaging.
    Nesteruk M; Nesteruk T; Styczyńska M; Barczak A; Mandecka M; Walecki J; Barcikowska-Kotowicz M
    Neurol Neurochir Pol; 2015; 49(6):349-53. PubMed ID: 26652867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting progression from mild cognitive impairment to Alzheimer's disease on an individual subject basis by applying the CARE index across different independent cohorts.
    Chen J; Chen G; Shu H; Chen G; Ward BD; Wang Z; Liu D; Antuono PG; Li SJ; Zhang Z;
    Aging (Albany NY); 2019 Apr; 11(8):2185-2201. PubMed ID: 31078129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation.
    Padovani A; Benussi A; Cantoni V; Dell'Era V; Cotelli MS; Caratozzolo S; Turrone R; Rozzini L; Alberici A; Altomare D; Depari A; Flammini A; Frisoni GB; Borroni B
    J Alzheimers Dis; 2018; 65(1):221-230. PubMed ID: 30010131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.
    Johnstone D; Milward EA; Berretta R; Moscato P;
    PLoS One; 2012; 7(4):e34341. PubMed ID: 22485168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The economics of mild cognitive impairment.
    Lin PJ; Neumann PJ
    Alzheimers Dement; 2013 Jan; 9(1):58-62. PubMed ID: 23141385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.